Pini L A, Ferrari A, Guidetti G, Galetti G, Sternieri E
Cephalalgia. 1985 May;5 Suppl 2:173-5. doi: 10.1177/03331024850050S233.
Flunarizine, a slow-channel calcium blocker, appeared to be effective in the prophylactic treatment of common and classic migraine in 29 out-patients included in a double-blind clinical trial. After a two-month placebo period, half the patients were treated with flunarizine, 10 mg a day for up to 120 days, half with placebo. Electronystagmographic (ENG) recordings were performed at the end of the common placebo period and after two and four months of treatment, respectively. There was a significant reduction in Headache Unit Index (HUI) and Headache Unit Index Corrected (HUIC) (42% and 40.5% respectively) in the flunarizine-treated group but not in the placebo group. Analgesic intake was reduced and intensity of pain was unchanged in both groups throughout the trial. ENG data were not significantly affected by flunarizine treatment.
氟桂利嗪是一种慢通道钙阻滞剂，在一项双盲临床试验纳入的29名门诊患者中，它似乎对常见型和典型偏头痛的预防性治疗有效。经过为期两个月的安慰剂期后，一半患者接受氟桂利嗪治疗，每日10毫克，持续长达120天，另一半患者接受安慰剂治疗。分别在普通安慰剂期结束时以及治疗两个月和四个月后进行眼震电图（ENG）记录。氟桂利嗪治疗组的头痛单位指数（HUI）和校正头痛单位指数（HUIC）显著降低（分别为42%和40.5%），而安慰剂组则未降低。在整个试验过程中，两组的镇痛药摄入量均减少，但疼痛强度均未改变。ENG数据未受到氟桂利嗪治疗的显著影响。
